SourceIT之家•Stalecollected in 3m
Scientists build first human heart bio-pacemaker organoid model
#biotech#organoid#cardiologyhuman-heart-bio-pacemaker-organoidchinese academy of sciencescell stem cell
A major breakthrough in bio-engineering and organoid research, offering a new human-centric platform for drug discovery.
30-Second TL;DR
What Changed
Successfully modeled the 'pacemaker-to-conduction' process using human pluripotent stem cells.
Why It Matters
This breakthrough bridges the gap between animal models and human physiology, significantly accelerating the development of personalized cardiac therapies and drug testing.
What To Do Next
Explore organoid-on-a-chip simulation software to integrate biological data into your computational drug discovery pipelines.
Who should care:Researchers & Academics
Key Points
- •Successfully modeled the 'pacemaker-to-conduction' process using human pluripotent stem cells.
- •Demonstrated neural regulation of heartbeats via a three-organoid assembly (nerve-pacemaker-atrium).
- •Identified the GPR37-PSAP signaling axis as a key mechanism for pacemaker maturation.
- •Validated the model's utility by replicating KCNJ3 mutation-induced arrhythmia phenotypes.
Deep Insight
Background and context from public sources — not the original article. 16 sources cited.
Enhanced Key Takeaways
- •The development of cardiac organoids has seen significant advancements from 2015 to 2025, moving from basic research tools to sophisticated platforms capable of multicellular integration, disease modeling, and biomaterial engineering, with recent efforts focusing on vascularization and AI integration.
- •Prior to this breakthrough, researchers had already developed various methods for generating biological pacemakers, including using viral gene therapy to overexpress or suppress ionic currents, and differentiating human induced pluripotent stem cells (hiPSCs) into spontaneously beating cardiomyocytes.
- •Recent studies have successfully engineered human sinoatrial node (SAN) organoids, sometimes referred to as 'Sinoids,' by integrating spatial multi-omics of human fetal SAN tissues with stem-cell engineering, allowing for the reconstruction of pacemaker-driven cardiac organization in vitro.
- •A key challenge in cardiac organoid development has been the lack of a functional blood vessel system, limiting their size and maturation; however, recent advancements in 2025 demonstrated the creation of heart organoids that generate their own blood vessels, potentially overcoming this bottleneck.
- •The multicellular composition and insulated architecture of the native sinoatrial node are crucial for robust pacemaking, and current research emphasizes reproducing this complex, heterogeneous structure in organoid models to achieve stable and long-term rhythmic activity, addressing limitations of single-cell type pacemakers.
Technical Deep Dive
- Stem Cell Source: Human pluripotent stem cells (hPSCs), including induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs), are used as the foundational cell source for differentiating into various cardiac cell types.
- Organoid Assembly: The model involves a three-organoid assembly: sinoatrial node organoids (SANOs or Sinoids), cardiac nerve plexus organoids, and atrial/ventricular cardioids, to mimic the 'pacemaker-to-conduction' process and neural regulation.
- Signaling Pathway Modulation: Wnt signaling pathway activation and inhibition are critical for guiding mesodermal induction and cardiogenic mesoderm induction during differentiation.
- Pacemaker Lineage Specification: High-resolution spatial transcriptomics and single-nucleus multi-omic analyses of human fetal SAN tissues are employed to identify regulatory pathways, such as YAP–TEAD and NRG–ERBB signaling, that guide pacemaker lineage specification.
- Genetic Reprogramming: Some approaches involve delivering dox-inducible genes for key pacemaker transcription factors like TBX-18 or Shox-2 via lentivirus to induce pacemaker cell identity in hiPSCs.
- Cellular Heterogeneity: Efforts focus on recapitulating the native SAN's cellular heterogeneity, including pacemaker cells (PCs), atrial cardiomyocytes (ACMs), transitional zone (TZ) cells, and stromal cells, with epicardial cells (Epics) contributing to stability and beat-to-beat regularity.
- Disease Modeling: The model's utility is validated by replicating arrhythmia phenotypes, such as those induced by KCNJ3 mutations.
Future ImplicationsAI analysis grounded in cited sources
This bio-pacemaker organoid model will significantly accelerate drug discovery for cardiac arrhythmias.
The model provides a human-specific, in vitro platform that can accurately replicate hereditary arrhythmia phenotypes and allow for high-throughput screening of therapeutic compounds, reducing reliance on animal models.
The technology could lead to the development of implantable biological pacemakers as an alternative to electronic devices.
By understanding and engineering the complex neural and cellular interactions that regulate heartbeats, this research moves closer to creating functional, autonomically responsive biological pacemakers that overcome limitations of current electronic implants.
Further research will focus on integrating vascularization and achieving greater maturation of these organoids.
The current size and maturity limitations of organoids due to lack of vascularization are a known bottleneck, and successful vascularization is crucial for creating larger, more physiologically relevant models and potential regenerative therapies.
Timeline
1950
First external pacemaker developed by Wilfred Bigelow and John Hopps.
1958
First successful implantation of a fully implantable electronic pacemaker in Sweden.
1979
Discovery of the 'funny' (If) current, a key mechanism in cardiac pacemaking, by Dario DiFrancesco.
2004
Kehat et al. demonstrate hESC-derived cardiomyocytes can integrate in vitro and provide autonomous pacing.
2015
Significant advancements in cardiac organoid development begin, focusing on multicellular integration and disease modeling.
2025-06
Stanford Medicine researchers develop heart and liver organoids capable of generating their own blood vessels.
- 1950First external pacemaker developed by Wilfred Bigelow and John Hopps.
- 1958First successful implantation of a fully implantable electronic pacemaker in Sweden.
- 1979Discovery of the 'funny' (If) current, a key mechanism in cardiac pacemaking, by Dario DiFrancesco.
- 2004Kehat et al. demonstrate hESC-derived cardiomyocytes can integrate in vitro and provide autonomous pacing.
- 2015Significant advancements in cardiac organoid development begin, focusing on multicellular integration and disease modeling.
- 2025-06Stanford Medicine researchers develop heart and liver organoids capable of generating their own blood vessels.
Sources (16)
Factual claims are grounded in the sources below. Forward-looking analysis is AI-generated interpretation.
1Google Search Sourcevertexaisearch.cloud.google.com2Google Search Sourcevertexaisearch.cloud.google.com3Google Search Sourcevertexaisearch.cloud.google.com4Google Search Sourcevertexaisearch.cloud.google.com5Google Search Sourcevertexaisearch.cloud.google.com6Google Search Sourcevertexaisearch.cloud.google.com7Google Search Sourcevertexaisearch.cloud.google.com8Google Search Sourcevertexaisearch.cloud.google.com9Google Search Sourcevertexaisearch.cloud.google.com10Google Search Sourcevertexaisearch.cloud.google.com11Google Search Sourcevertexaisearch.cloud.google.com12Google Search Sourcevertexaisearch.cloud.google.com13Google Search Sourcevertexaisearch.cloud.google.com14Google Search Sourcevertexaisearch.cloud.google.com15Google Search Sourcevertexaisearch.cloud.google.com16Google Search Sourcevertexaisearch.cloud.google.com
Weekly AI Recap
Read this week's curated digest of top AI events →
AI-curated news aggregator. All content rights belong to original publishers.
Original source: IT之家 ↗
This is a summary, not the original. Read the source, or get the weekly briefing.
The weekly digest
One email a week. Unsubscribe anytime.